shutterstock_1036579204.png

News

Azora Therapeutics Enrolls First Patient in Clinical Trial of AT-193, a Potential Treatment for Hidradenitis Suppurativa

Los Angeles CA - October 19, 2021 - Azora Therapeutics Inc., a biopharmaceutical company focused on developing treatments for serious inflammatory diseases, announced today that the first patient has been enrolled in trial HS01, a phase 1b multicenter, randomized, double-blind, placebo-controlled study of topical AT193 for the treatment of mild-to-moderate hidradenitis suppurativa (HS). The study is designed to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of AT-193 and is expected to enroll 40 patients with mild-to-moderate HS at multiple sites in Australia.

Hidradenitis suppurativa (HS) is a debilitating, chronic autoinflammatory disease affecting the apocrine gland-bearing skin.  HS typically manifests as painful inflammatory nodules in the armpits, breasts, groin, and buttocks. Sustained inflammation contributes to the formation of abscesses, fistulas, and sinus tracts.  Disease can be progressive, ranging from mild to severe, and can span decades in duration. The pathology of HS is poorly understood but involves microbial dysbiosis and an autoinflammatory response. Patients with HS have significantly impaired quality of life due to physical and psychological discomfort associated with the disease. There are no FDA-approved medications for the treatment of mild-to-moderate HS.

“Patients with mild-to-moderate HS may have fewer nodules or abscesses, but they still cause considerable pain and have the potential to rupture and drain onto clothing.  A treatment option for these patients, preferably a convenient topical therapy, is sorely needed" stated Dr. Martin Okun, Azora Clinical Advisor and HS expert who helped design the pivotal phase 3 trials of adalimumab (Humira®) for moderate-to-severe HS that resulted in the first and only FDA-approved product for the disease.

About Azora

Azora Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious inflammatory diseases.  The company was spun out of Stanford University after being incubated in the translational medicine SPARK program.  Azora owns the worldwide royalty-free rights to its technology, which is based on the development of potential best-in-class and first-in-class oral and topical agonists of the aryl hydrocarbon receptor.  More information on Azora and its pipeline can be found on the company's website at www.AzoraTherapeutics.com.

Azora Therapeutics Completes $8M Series A Financing

Los Angeles CA - June 1, 2021 - Azora Therapeutics Inc., a biopharmaceutical company focused on developing treatments for serious inflammatory diseases, announced the closing of a $8M Series A financing.  Acclaimed Stanford University Medical School Professors and biotech founders participated in the round including the founders of Forty-Seven Therapeutics, Dendreon, and Neurocrine Biosciences.

Proceeds from the Series A will support the advancement of Azora's topical and oral programs for the treatment of Hidradenitis Suppurativa (HS), Ulcerative Colitis (UC), and unspecified programs.  The company expects to begin clinical trials for HS Q4 2021.

Concurrent with the close of the financing, Azora announced that biotech veteran Dennis Brown, PhD, founder of ChemGenex Therapeutics, Matrix Pharmaceutics, and Kintara Therapeutics, has been nominated to join Azora's Board of Directors.  "Dr. Brown has been a long time advisor and has more than thirty years of drug discovery and development experience.  We welcome his creativity and strategic direction as we take Azora into its next stages," stated Matt Davidson, PhD, Chief Executive Officer of Azora.

About Azora

Azora Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious inflammatory diseases.  The company was spun out of Stanford University after being incubated in the translational medicine SPARK program.  Azora owns the worldwide royalty-free rights to its technology, which is based on the development of potential best-in-class and first-in-class oral and topical agonists of the aryl hydrocarbon receptor.  More information on Azora and its pipeline can be found on the company's website at www.AzoraTherapeutics.com.